

**REMARKS**

In response to the Restriction Requirement, Applicants hereby elect Group I, claims 56, 61-69, 82-84, 86, and 102-105 for examination in this application. Applicants request that claims 70 and 76 be reinstated. Claims 57-60, 71-75, 77-81, 85, and 87-101 are withdrawn. New claim 106 is added. Claims 1-55 are canceled without prejudice to the subject matter therein, and Applicants reserve the right to prosecute them in such divisional or continuation application as may be filed at a later date.

Referring to the Action mailed May 15, 2007, concerning species A, Applicants elect an ectodomain and a transmembrane domain of the baculovirus GP64 protein and a C-terminal sequence of a respiratory syncytial virus fusion protein F. For species B, Applicants elect the temperature of above about 0°C and the storage condition of at least 3.5 days. Regarding species C, Applicants elect 40% as the percentage of viral infectivity reduction of wild-type human respiratory syncytial virus A2. Concerning species D, Applicants elect one immunogenic epitope. For species E, Applicants elect the cytoplasmic tail as the heterologous domain. Finally, regarding species F, Applicants have withdrawn claim 93, rendering this election moot.

In view of the above elections and remarks, examination on the merits of all of the pending claims is believed to be in order and consideration and allowance of the instant application is respectfully requested.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully submitted,

/Mary S. Webster, Reg. No. #37,156

Mary S. Webster

NIXON PEABODY LLP  
401 9th Street, N.W., Suite 900  
Washington, DC 20004-2128  
(202) 585-8000